Peter Gmeiner

In vivo monitoring of the antiangiogenic effect of neurotensin receptor-mediated radiotherapy by small-animal positron emission tomography: a pilot study.

Covalent agonists for studying G protein-coupled receptor activation.

Synthesis and binding profile of haloperidol-based bivalent ligands targeting dopamine D(2)-like receptors.

Structure-based evolution of subtype-selective neurotensin receptor ligands.

Selective GPCR ligands.

1,4-Disubstituted aromatic piperazines with high 5-HT2A/D2 selectivity: Quantitative structure-selectivity investigations, docking, synthesis and biological evaluation.

Arrestin-Bound Rhodopsin: A Molecular Structure and its Impact on the Development of Biased GPCR Ligands.

Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.

NTS2-selective neurotensin mimetics with tetrahydrofuran amino acids.

Theranostic Value of Multimers: Lessons Learned from Trimerization of Neurotensin Receptor Ligands and Other Targeting Vectors.

Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased DR Agonists.

Development of molecular tools based on the dopamine D receptor ligand FAUC 329 showing inhibiting effects on drug and food maintained behavior.

Potent haloperidol derivatives covalently binding to the dopamine D2 receptor.

β-Arrestin biased dopamine D2 receptor partial agonists: Synthesis and pharmacological evaluation.

Visualization of ligand-induced dopamine D and D receptor internalization by TIRF microscopy.

Structure-guided development of selective M3 muscarinic acetylcholine receptor antagonists.

Monitoring of the dopamine D2 receptor agonists hordenine and N-methyltyramine during the brewing process and in commercial beer samples.

Development of covalent antagonists for β1- and β2-adrenergic receptors.

Structure-based exploration of an allosteric binding pocket in the NTS1 receptor using bitopic NT(8-13) derivatives and molecular dynamics simulations.

Rational design of agonists for bitter taste receptor TAS2R14: from modeling to bench and back.